Enanta Pharmaceuticals (ENTA) Stock: Why It's Up Today
Updated Oct 20, 2026, 1:16 PM ET · intraday price
- Trading at $11.67 as of 1:16 PM ET, +2.28% vs the prior close of $11.41.
- Volume 65.37K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)
ENTA rises 2.3% to $11.67. Trading at $11.67 (intraday, 1:16 PM ET), +2.28% vs the prior close of $11.41. Day range $11.41–$11.76, opened at $11.43.
ENTA daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — ENTA rises 2.3% to $11.67
- Trading at $11.67 (intraday, 1:16 PM ET), +2.28% vs the prior close of $11.41. Day range $11.41–$11.76, opened at $11.43.
- Volume was 65.37K shares, 0.3x its 50-day average of 253.55K — lighter than usual.
- Price is -8.9% vs its 50-day average ($12.82) and -12.1% vs its 200-day average ($13.27).
- 52-week range $10.20–$17.15; the current price sits at 21% of that range, 32.0% below the 52-week high.
Oct 19, 2026 — ENTA rises 2.8% to $11.41
- Closed at $11.41, +2.79% vs the prior close of $11.10. Day range $11.00–$11.75, opened at $11.14.
- Volume was 293.41K shares, 1.2x its 50-day average of 251.34K.
- Price is -11.3% vs its 50-day average ($12.86) and -14.1% vs its 200-day average ($13.29).
- 52-week range $10.20–$17.15; today's close sits at 17% of that range, 33.5% below the 52-week high.
Oct 16, 2026 — ENTA slides 3.2% to $11.10, a 3-month low
- Closed at $11.10, -3.23% vs the prior close of $11.47. Day range $10.94–$11.62, opened at $11.45.
- Volume was 215.41K shares, 0.9x its 50-day average of 251.44K.
- Price is -14.0% vs its 50-day average ($12.91) and -16.6% vs its 200-day average ($13.31).
- 52-week range $10.20–$17.15; today's close sits at 13% of that range, 35.3% below the 52-week high.
Oct 15, 2026 — ENTA rises 2.6% to $11.47
- Closed at $11.47, +2.59% vs the prior close of $11.18. Day range $11.22–$11.75, opened at $11.34.
- Volume was 178.40K shares, 0.7x its 50-day average of 252.48K.
- Price is -11.4% vs its 50-day average ($12.95) and -14.0% vs its 200-day average ($13.33).
- 52-week range $10.20–$17.15; today's close sits at 18% of that range, 33.1% below the 52-week high.
Oct 14, 2026 — ENTA dips 3.0% to $11.18, a 3-month low, 3 down days in a row
- Closed at $11.18, -2.95% vs the prior close of $11.52. Day range $11.15–$11.56, opened at $11.44.
- Volume was 227.60K shares, 0.9x its 50-day average of 252.12K.
- Price is -13.9% vs its 50-day average ($12.99) and -16.3% vs its 200-day average ($13.36).
- 52-week range $10.20–$17.15; today's close sits at 14% of that range, 34.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ENTA slides 6.3% to $11.52, a 3-month low
- Closed at $11.52, -6.34% vs the prior close of $12.30. Day range $11.39–$12.37, opened at $12.37.
- Volume was 174.00K shares, 0.7x its 50-day average of 252.00K.
- Price is -11.6% vs its 50-day average ($13.03) and -13.9% vs its 200-day average ($13.39).
- 52-week range $10.20–$17.15; today's close sits at 19% of that range, 32.8% below the 52-week high.
Oct 12, 2026 — ENTA dips 1.6% to $12.30
- Closed at $12.30, -1.60% vs the prior close of $12.50. Day range $12.15–$12.64, opened at $12.48.
- Volume was 122.90K shares, 0.5x its 50-day average of 252.41K — lighter than usual.
- Price is -5.8% vs its 50-day average ($13.06) and -8.3% vs its 200-day average ($13.41).
- 52-week range $10.20–$17.15; today's close sits at 30% of that range, 28.3% below the 52-week high.
Oct 9, 2026 — ENTA jumps 3.3% to $12.50
- Closed at $12.50, +3.31% vs the prior close of $12.10. Day range $12.07–$12.61, opened at $12.07.
- Volume was 182.10K shares, 0.7x its 50-day average of 251.62K.
- Price is -4.3% vs its 50-day average ($13.06) and -6.9% vs its 200-day average ($13.43).
- 52-week range $10.20–$17.15; today's close sits at 33% of that range, 27.1% below the 52-week high.
Oct 8, 2026 — ENTA dips 2.2% to $12.10
- Closed at $12.10, -2.18% vs the prior close of $12.37. Day range $11.70–$12.35, opened at $12.26.
- Volume was 282.90K shares, 1.1x its 50-day average of 248.91K.
- Price is -7.4% vs its 50-day average ($13.07) and -10.0% vs its 200-day average ($13.45).
- 52-week range $10.20–$17.15; today's close sits at 27% of that range, 29.4% below the 52-week high.
Oct 7, 2026 — ENTA rises 1.6% to $12.37
- Closed at $12.37, +1.64% vs the prior close of $12.17. Day range $12.05–$12.57, opened at $12.09.
- Volume was 191.70K shares, 0.8x its 50-day average of 248.62K.
- Price is -5.4% vs its 50-day average ($13.08) and -8.1% vs its 200-day average ($13.46).
- 52-week range $10.20–$17.15; today's close sits at 31% of that range, 27.9% below the 52-week high.
Oct 6, 2026 — ENTA slides 3.4% to $12.17
- Closed at $12.17, -3.41% vs the prior close of $12.60. Day range $11.97–$12.66, opened at $12.66.
- Volume was 271.70K shares, 1.1x its 50-day average of 245.02K.
- Price is -7.0% vs its 50-day average ($13.09) and -9.7% vs its 200-day average ($13.47).
- 52-week range $10.20–$17.15; today's close sits at 28% of that range, 29.0% below the 52-week high.
Oct 5, 2026 — ENTA dips 2.8% to $12.60
- Closed at $12.60, -2.78% vs the prior close of $12.96. Day range $12.47–$13.02, opened at $12.95.
- Volume was 218.90K shares, 0.9x its 50-day average of 242.74K.
- Price is -3.8% vs its 50-day average ($13.10) and -6.6% vs its 200-day average ($13.48).
- 52-week range $10.12–$17.15; today's close sits at 35% of that range, 26.5% below the 52-week high.
Oct 2, 2026 — ENTA rises 0.9% to $12.96 on 3.2x normal volume
- Closed at $12.96, +0.93% vs the prior close of $12.84. Day range $12.58–$13.21, opened at $13.20.
- Volume was 748.00K shares, 3.2x its 50-day average of 230.36K — unusually heavy trading.
- Price is -1.1% vs its 50-day average ($13.10) and -4.0% vs its 200-day average ($13.50).
- 52-week range $10.09–$17.15; today's close sits at 41% of that range, 24.4% below the 52-week high.
ENTA bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Price is -8.9% vs its 50-day average — short-term trend is down.
- Price is -12.1% vs its 200-day average — below the long-term trend line.
- Annual revenue fell 3.4% in the latest fiscal year (SEC XBRL).
- Latest fiscal-year net income: loss of $81.89M.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
- Share count up 36.2% in a year (dilution).
ENTA latest news & SEC filings
Every SEC filing by or about ENTA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $14.36M (prior year $18.31M) (-21.6% vs Jun 30, 2025)
- Net income: -$19.50M (prior year -$18.25M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.67 (prior year -$0.85) (loss narrowed vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Jul 2, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade ENTA
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Feb 9, 2026, Nov 17, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.72% (largest 6.3%).
- Liquidity: about 261.58K shares (≈$3.05M) trade per day on average.
- 52-week position: $11.67 vs a range of $10.20–$17.15 (21% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Kathleen S. Capps sold 323 shares on Dec 5, 2025.
- Latest filings: 10-Q Aug 12, 2026; 8-K Aug 10, 2026; 8-K Jul 2, 2026.
- Share count: 29.13M shares outstanding (Aug 7, 2026), +36.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ENTA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 11.43 | 11.76 | 11.41 | 11.67 | 65.37K |
| Oct 19, 2026 | 11.14 | 11.76 | 11.00 | 11.41 | 293.40K |
| Oct 16, 2026 | 11.65 | 11.65 | 10.94 | 11.10 | 215.40K |
| Oct 15, 2026 | 11.34 | 11.75 | 11.22 | 11.47 | 178.40K |
| Oct 14, 2026 | 11.44 | 11.56 | 11.15 | 11.18 | 227.60K |
| Oct 13, 2026 | 12.37 | 12.37 | 11.39 | 11.52 | 174.00K |
| Oct 12, 2026 | 12.48 | 12.64 | 12.15 | 12.30 | 122.90K |
| Oct 9, 2026 | 12.07 | 12.61 | 12.07 | 12.50 | 182.10K |
| Oct 8, 2026 | 12.26 | 12.35 | 11.70 | 12.10 | 282.90K |
| Oct 7, 2026 | 12.09 | 12.57 | 12.05 | 12.37 | 191.70K |
| Oct 6, 2026 | 12.66 | 12.66 | 11.97 | 12.17 | 271.70K |
| Oct 5, 2026 | 12.95 | 13.02 | 12.47 | 12.60 | 218.90K |
| Oct 2, 2026 | 13.20 | 13.21 | 12.58 | 12.96 | 748.00K |
| Oct 1, 2026 | 13.08 | 13.45 | 12.83 | 12.84 | 331.50K |
| Sep 30, 2026 | 12.67 | 13.41 | 12.44 | 13.18 | 425.90K |
| Sep 29, 2026 | 12.62 | 12.85 | 12.43 | 12.64 | 322.80K |
| Sep 28, 2026 | 11.88 | 12.68 | 11.69 | 12.61 | 349.30K |
| Sep 25, 2026 | 11.99 | 12.00 | 11.64 | 11.88 | 217.30K |
| Sep 24, 2026 | 11.94 | 12.02 | 11.67 | 12.00 | 206.20K |
| Sep 23, 2026 | 12.33 | 12.33 | 11.87 | 11.95 | 206.30K |
About Enanta Pharmaceuticals
Enanta Pharmaceuticals (ENTA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WATERTOWN, MA. Fiscal year ends September 30. SEC CIK 1177648.
ENTA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Bruce L A Carter | Director | Mar 13, 2026 |
| Mark G Foletta | Director | Mar 13, 2026 |
| Yujiro S Hata | Director | Mar 13, 2026 |
| Jay R. Luly | President and CEO | Feb 13, 2026 |
| Kristine Peterson | Director | Mar 13, 2026 |
| Lesley Russell | Director | Mar 13, 2026 |
| Terry Vance | Director | Mar 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kathleen S. Capps | See Remarks | Dec 5, 2025 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | Feb 13, 2026 |
| Matthew Paul Kowalsky | Chief Legal Officer | Feb 13, 2026 |
| Jay R. Luly | President and CEO | Feb 13, 2026 |
| Brendan Luu | Chief Business Officer | Feb 13, 2026 |
| Yat Sun Or | Chief Scientific Officer | Feb 13, 2026 |
| Scott T. Rottinghaus | Chief Medical Officer | Aug 10, 2026 |
| Harry R. Iii Trout | See Remarks | Dec 5, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 5, 2025 | Kathleen S. Capps | Sale | 323 | $14.23 |
| Dec 5, 2025 | Kathleen S. Capps | Sale | 323 | $14.23 |
| Dec 5, 2025 | Kathleen S. Capps | Sale | 323 | $14.23 |
| Dec 5, 2025 | Kathleen S. Capps | Sale | 323 | $14.23 |
| Dec 5, 2025 | Yat Sun Or | Sale | 2,390 | $14.23 |
| Dec 5, 2025 | Yat Sun Or | Sale | 2,390 | $14.23 |
| Dec 5, 2025 | Yat Sun Or | Sale | 2,390 | $14.23 |
| Dec 5, 2025 | Yat Sun Or | Sale | 2,390 | $14.23 |
| Dec 5, 2025 | Scott T. Rottinghaus | Sale | 798 | $14.23 |
| Dec 5, 2025 | Scott T. Rottinghaus | Sale | 798 | $14.23 |
| Dec 5, 2025 | Scott T. Rottinghaus | Sale | 798 | $14.23 |
| Dec 5, 2025 | Scott T. Rottinghaus | Sale | 798 | $14.23 |
| Dec 5, 2025 | Brendan Luu | Sale | 1,394 | $14.23 |
| Dec 5, 2025 | Brendan Luu | Sale | 1,394 | $14.23 |
| Dec 5, 2025 | Brendan Luu | Sale | 1,394 | $14.23 |
ENTA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Sep 30, 2025 | $65.32M | $-81.89M | -3.84 | $-19.27M |
| Sep 30, 2024 | $67.64M | $-116.05M | -5.48 | $-78.76M |
| Sep 30, 2023 | $79.20M | $-133.82M | -6.38 | $-103.15M |
| Sep 30, 2022 | $86.16M | $-121.75M | -5.91 | $-84.78M |
| Sep 30, 2021 | $97.07M | $-79.00M | -3.92 | $-70.00M |
Latest balance sheet: total assets $296.87M, total liabilities $195.80M, cash $33.42M (as of Jun 30, 2026).
ENTA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $13.81 |
| May 11, 2026 | 8-K Item 2.02 (results) | $15.46 |
| Feb 9, 2026 | 8-K Item 2.02 (results) | $13.83 |
| Nov 17, 2025 | 8-K Item 2.02 (results) | $12.82 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $6.49 |
| May 12, 2025 | 8-K Item 2.02 (results) | $5.55 |
| Feb 10, 2025 | 8-K Item 2.02 (results) | $4.90 |
| Nov 25, 2024 | 8-K Item 2.02 (results) | $9.01 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Feb 7, 2024 | 8-K Item 2.02 (results) | — |
| Nov 20, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)United Therapeutics (UTHR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on ENTA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 20, 2026, 1:16 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.